High-affinity ligands of Siglec receptors and their therapeutic potentials.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Current Medicinal Chemistry

• Publication date

  2011-07-31

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2174/092986711796642580PMID 21756229
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evolution of CD33‐related siglecs: regulating host immune functions and escaping pathogen exploitation?

  2011cited by this paper
• CD22-antagonists with nanomolar potency: the synergistic effect of hydrophobic groups at C-2 and C-9 of sialic acid scaffold.

  2011cited by this paper
• Alleviation of Neurotoxicity by Microglial Human Siglec-11

  2010cited by this paper
• Uniquely human evolution of sialic acid genetics and biology

  2010cited by this paper
• Design, synthesis, biological evaluation, and modeling of a non-carbohydrate antagonist of the myelin-associated glycoprotein.

  2010cited by this paper
• In vivo targeting of B-cell lymphoma with glycan ligands of CD22.

  2010cited by this paper
• Receptors for myelin inhibitors: Structures and therapeutic opportunities.

  2010cited by this paper
• Low molecular weight antagonists of the myelin-associated glycoprotein: synthesis, docking, and biological evaluation.

  2010cited by this paper
• Kinetic and thermodynamic properties of MAG antagonists.

  2010cited by this paper
• Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial

  2010cited by this paper
• Brain gangliosides in axon–myelin stability and axon regeneration

  2010cited by this paper
• Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes

  2010cited by this paper
• Advances in the biology and chemistry of sialic acids.

  2010cited by this paper
• Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma

  2010cited by this paper
• Characterization of the Specific Interaction between Sialoadhesin and Sialylated Campylobacter jejuni Lipooligosaccharides

  2010cited by this paper
• Siglec‐8 on human eosinophils and mast cells, and Siglec‐F on murine eosinophils, are functionally related inhibitory receptors

  2009cited by this paper
• Siglecs as targets for therapy in immune-cell-mediated disease.

  2009cited by this paper
• Human Siglec-10 can bind to vascular adhesion protein-1 and serves as its substrate.

  2009cited by this paper
• Potent small molecule mouse CD22-inhibitors: exploring the interaction of the residue at C-2 of sialic acid scaffold.

  2009cited by this paper
• CD22 and Siglec‐G: B‐cell inhibitory receptors with distinct functions

  2009cited by this paper
• Siglec receptors and hiding plaques in Alzheimer's disease

  2009cited by this paper
• Examination of the biological role of the alpha(2-->6)-linked sialic acid in gangliosides binding to the myelin-associated glycoprotein (MAG).

  2009cited by this paper
• Deletion polymorphism of SIGLEC14 and its functional implications.

  2009cited by this paper
• Siglec-1 on monocytes is a potential risk marker for monitoring disease severity in coronary artery disease.

  2009cited by this paper
• Sialic acids in T cell development and function.

  2009cited by this paper
• Sialoadhesin-Positive Macrophages Bind Regulatory T Cells, Negatively Controlling Their Expansion and Autoimmune Disease Progression1

  2009cited by this paper
• CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells

  2009cited by this paper
• Sialic acids as regulators of molecular and cellular interactions

  2009cited by this paper
• Molecular mimicry of host sialylated glycans allows a bacterial pathogen to engage neutrophil Siglec-9 and dampen the innate immune response.

  2009cited by this paper
• Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia

  2008cited by this paper
• Sialoadhesin Expressed on IFN-Induced Monocytes Binds HIV-1 and Enhances Infectivity

  2008cited by this paper
• Bifunctional CD22 ligands use multimeric immunoglobulins as protein scaffolds in assembly of immune complexes on B cells.

  2008cited by this paper
• CD22: an inhibitory enigma

  2008cited by this paper
• Structural implications of Siglec‐5 mediated sialo‐glycan recognition

  2008cited by this paper
• Sialic acids in human health and disease.

  2008cited by this paper
• Siglecs as positive and negative regulators of the immune system.

  2008cited by this paper
• Combinatorial chemoenzymatic synthesis and high-throughput screening of sialosides.

  2008cited by this paper
• Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus.

  2008cited by this paper
• Design, synthesis, and structure-affinity relationships of novel series of sialosides as CD22-specific inhibitors.

  2008cited by this paper
• Basic and Clinical Immunology of Siglecs

  2008cited by this paper
• Binding Epitopes of Gangliosides to their Neuronal Receptor, Myelin‐Associated Glycoprotein, from Saturation Transfer Difference NMR

  2008cited by this paper
• SIGLEC16 encodes a DAP12‐associated receptor expressed in macrophages that evolved from its inhibitory counterpart SIGLEC11 and has functional and non‐functional alleles in humans

  2008cited by this paper
• CD22 Regulates Time Course of Both B Cell Division and Antibody Response1

  2008cited by this paper
• Axon regeneration inhibitors

  2008cited by this paper
• Sialoside analogue arrays for rapid identification of high affinity siglec ligands.

  2008cited by this paper
• Synthesis of sialic acid derivatives as ligands for the myelin-associated glycoprotein (MAG).

  2007cited by this paper
• Intravenous immunoglobulin preparations contain anti-Siglec-8 autoantibodies.

  2007cited by this paper
• Human-specific expression of Siglec-6 in the placenta.

  2007cited by this paper
• Siglecs and their roles in the immune system

  2007cited by this paper
• Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies

  2007cited by this paper
• N-Glycolylneuraminic Acid Deficiency in Mice: Implications for Human Biology and Evolution

  2007cited by this paper
• Diversity in cell surface sialic acid presentations: implications for biology and disease

  2007cited by this paper
• Myelin‐associated glycoprotein (MAG): past, present and beyond

  2007cited by this paper
• The acute‐phase protein α1‐acid glycoprotein (AGP) induces rises in cytosolic Ca2+ in neutrophil granulocytes via sialic acid binding immunoglobulin‐like lectins (Siglecs)

  2007cited by this paper
• Crystallographic and in silico analysis of the sialoside-binding characteristics of the Siglec sialoadhesin.

  2007cited by this paper
• Mimetics of the tri- and tetrasaccharide epitope of GQ1balpha as myelin-associated glycoprotein (MAG) ligands.

  2007cited by this paper
• Human B-lymphocytes Express α2-6-Sialylated 6-Sulfo-N-acetyllactosamine Serving as a Preferred Ligand for CD22/Siglec-2*

  2007cited by this paper
• Siglec-15: an immune system Siglec conserved throughout vertebrate evolution.

  2007cited by this paper
• Analysis of the CD33-related siglec family reveals that Siglec-9 is an endocytic receptor expressed on subsets of acute myeloid leukemia cells and absent from normal hematopoietic progenitors.

  2007cited by this paper
• Alteration and acquisition of Siglecs during in vitro maturation of CD34+ progenitors into human mast cells

  2006cited by this paper
• Discovery of Siglec‐14, a novel sialic acid receptor undergoing concerted evolution with Siglec‐5 in primates

  2006cited by this paper
• High-Affinity Ligand Probes of CD22 Overcome the Threshold Set by cis Ligands to Allow for Binding, Endocytosis, and Killing of B Cells1

  2006cited by this paper
• Antagonists of the myelin-associated glycoprotein: a new class of tetrasaccharide mimics.

  2006cited by this paper
• Siglec-7 Undergoes a Major Conformational Change When Complexed with the α(2,8)-Disialylganglioside GT1b*

  2006cited by this paper
• The structure of siglec-7 in complex with sialosides: leads for rational structure-based inhibitor design.

  2006cited by this paper
• Sialic Acid-Binding Immunoglobulin-Like Lectin 7 Mediates Selective Recognition of Sialylated Glycans Expressed on Campylobacter jejuni Lipooligosaccharides

  2006cited by this paper
• Epratuzumab (humanised anti-CD22 antibody) in autoimmune diseases

  2006cited by this paper
• Probing the cis interactions of the inhibitory receptor Siglec‐7 with α2,8‐disialylated ligands on natural killer cells and other leukocytes using glycan‐specific antibodies and by analysis of α2,8‐sialyltransferase gene expression

  2006cited by this paper
• Siglecs--the major subfamily of I-type lectins.

  2006cited by this paper
• Molecular diversity and evolution of the Siglec family of cell-surface lectins

  2006cited by this paper
• Potent Glycan Inhibitors of Myelin-associated Glycoprotein Enhance Axon Outgrowth in Vitro*

  2005cited by this paper
• Human Rhinoviruses Inhibit the Accessory Function of Dendritic Cells by Inducing Sialoadhesin and B7-H1 Expression1

  2005cited by this paper
• Increased association of Trypanosoma cruzi with sialoadhesin positive mice macrophages

  2005cited by this paper
• Siglec-9 transduces apoptotic and nonapoptotic death signals into neutrophils depending on the proinflammatory cytokine environment.

  2005cited by this paper
• Glycan Array Screening Reveals a Candidate Ligand for Siglec-8*

  2005cited by this paper
• Siglecs in innate immunity.

  2005cited by this paper
• CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance

  2005cited by this paper
• Large-scale sequencing of the CD33-related Siglec gene cluster in five mammalian species reveals rapid evolution by multiple mechanisms.

  2004cited by this paper
• Saturation transfer difference NMR and computational modeling of a sialoadhesin-sialyl lactose complex.

  2004cited by this paper
• CD33/Siglec-3 Binding Specificity, Expression Pattern, and Consequences of Gene Deletion in Mice

  2003cited by this paper
• Recognition of sialylated meningococcal lipopolysaccharide by siglecs expressed on myeloid cells leads to enhanced bacterial uptake

  2003cited by this paper
• Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis.

  2003cited by this paper
• Sialoside Specificity of the Siglec Family Assessed Using Novel Multivalent Probes

  2003cited by this paper
• Structure-guided design of sialic acid-based Siglec inhibitors and crystallographic analysis in complex with sialoadhesin.

  2003cited by this paper
• High Resolution Crystal Structures of Siglec-7

  2003cited by this paper
• Chemically defined sialoside scaffolds for investigation of multivalent interactions with sialic acid binding proteins.

  2003cited by this paper
• Human Siglec‐5: tissue distribution, novel isoforms and domain specificities for sialic acid‐dependent ligand interactions

  2002cited by this paper
• Gangliosides are functional nerve cell ligands for myelin-associated glycoprotein (MAG), an inhibitor of nerve regeneration

  2002cited by this paper
• The Ligand-binding Domain of CD22 Is Needed for Inhibition of the B Cell Receptor Signal, as Demonstrated by a Novel Human CD22-specific Inhibitor Compound

  2002cited by this paper
• CD33 as a target for selective ablation of acute myeloid leukemia.

  2002cited by this paper
• Chemical diversity in the sialic acids and related alpha-keto acids: an evolutionary perspective.

  2002cited by this paper
• Cloning and Characterization of Human Siglec-11

  2002cited by this paper
• Siglecs: sialic-acid-binding immunoglobulin-like lectins in cell-cell interactions and signalling.

  2002cited by this paper
• A small region of the natural killer cell receptor, Siglec-7, is responsible for its preferred binding to alpha 2,8-disialyl and branched alpha 2,6-sialyl residues. A comparison with Siglec-9.

  2002cited by this paper
• Siglecs, sialic acids and innate immunity.

  2001cited by this paper
• Cloning and Characterization of Siglec-10, a Novel Sialic Acid Binding Member of the Ig Superfamily, from Human Dendritic Cells*

  2001cited by this paper
• A new siglec family member, siglec-10, is expressed in cells of the immune system and has signaling properties similar to CD33.

  2001cited by this paper
• A Second Uniquely Human Mutation Affecting Sialic Acid Biology* 210

  2001cited by this paper
• Identification, characterization and leucocyte expression of Siglec-10, a novel human sialic acid-binding receptor.

  2001cited by this paper
• Surface expression and function of p75/AIRM-1 or CD33 in acute myeloid leukemias: Engagement of CD33 induces apoptosis of leukemic cells

  2001cited by this paper

• The Role of Glycans in Human Immunity—A Sweet Code

  2025cites this paper
• Molecular Insights into the Engagement of High-Affinity Sialylated Ligands to Human CD22

  2025cites this paper
• Siglecs in immunotherapy: current clinical landscape and prospects.

  2025cites this paper
• Sialylation-dependent interaction between PD-L1 and CD169 promotes monocytes adhesion to endothelial cells.

  2023cites this paper
• Recent progress in targeting the sialylated glycan-SIGLEC axis in cancer immunotherapy

  2023cites this paper
• Sequence variety in the CC’ loop of Siglec-8/9/3 determines the recognitions to sulfated oligosaccharides

  2023cites this paper
• Glycosyltransferases as targets for therapeutic intervention in cancer and inflammation: molecular modeling insights

  2022cites this paper
• Oligodendroglial glycolipids in (Re)myelination: implications for multiple sclerosis research.

  2021cites this paper
• Introduction to Comprehensive Glycoscience: The Good, the Better and What's to Come

  2021cites this paper
• Sialic acids in autoimmune disorders

  2020cites this paper
• Tumor Derived SIGLEC Family Genes May Play Roles in Tumor Genesis, Progression, and Immune Microenvironment Regulation

  2020cites this paper
• A sulfonamide sialoside analog for targeting Siglec-8 and -F on im-mune cells.

  2019cites this paper
• New Human CD22/Siglec‐2 Ligands with a Triazole Glycoside

  2017cites this paper
• Mast cell and eosinophil surface receptors as targets for anti‐allergic therapy

  2017influential citation
• Turning-Off Signaling by Siglecs, Selectins, and Galectins: Chemical Inhibition of Glycan-Dependent Interactions in Cancer

  2016cites this paper
• A Peptide Mimetic of 5-Acetylneuraminic Acid-Galactose Binds with High Avidity to Siglecs and NKG2D

  2015cites this paper
• Sialic acids in the brain: gangliosides and polysialic acid in nervous system development, stability, disease, and regeneration.

  2014cites this paper
• Strategies in the Design of Small‐Molecule Fluorescent Probes for Peptidases

  2014cites this paper
• MOLECULAR CONCEPTS OF MACROPHAGE TARGETING

  2013cites this paper
• Protein Glycosylation, an Overview

  2012cites this paper
• In silico-aided design of a glycan ligand of sialoadhesin for in vivo targeting of macrophages.

  2012cites this paper
• Multifarious roles of sialic acids in immunity

  2012cites this paper
• Pathogenic impact of immune-related cells in Batten disease

  2012cites this paper
• CD33‐related siglecs as potential modulators of inflammatory responses

  2012cites this paper
• Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions.

  2012cites this paper